Munich (OTE) – Innovative Molecules GmbH Announces Completion of
Phase 1b Enrollment
for IM-250 in Genital Herpes Clinical Trial

Innovative Molecules GmbH today announced the completion of
enrollment in the Phase 1b portion of its ongoing Phase 1b/2a
clinical trial evaluating IM-250, a next-generation helicase-primase
inhibitor targeting herpes simplex virus (HSV).

This placebo-controlled study is designed to assess the safety,
efficacy, and pharmacokinetics of once-weekly oral dosing of IM-250
in patients with recurrent genital herpes. The successful completion
of Phase 1b enrollment marks a key inflection point in the program,
supporting the continued clinical development of IM-250 and its
potential to reshape a market that has seen little therapeutic
innovation in over four decades.

“Completing Phase 1b enrollment represents a significant
milestone not only for our clinical program but also for patients who
continue to face the burden of recurrent genital herpes with limited
treatment options,” said Dr. Anja Glaessing, Head of Medical Affairs
at Innovative Molecules.

Topline results from the Phase 1b portion of the study are
expected in H2, 2025.

About IM-250

IM-250 is a novel, orally available, selective HSV-helicase
primase inhibitor. Helicase primase inhibitors block DNA unwinding in
the replication fork during viral DNA-replication by a potentially
uncompetitive mechanism of action. IM-250, due to its optimized
molecular structure, is likely to improve target tissue penetration (
neural and brain tissue), achieving adequate therapeutic exposure at
the site of HSV reservoir.

About Innovative Molecules

Innovative Molecules GmbH is a drug development company based in
Munich, Germany. With the aim to set a new treatment standard for
herpes simplex induced diseases, the company is focused on the
development of IM-250, a potent, second-generation helicase-primase
inhibitor of HSV-1 and HSV-2.

For more information visit www.innovativemolecules.com

Logo –
https://mma.prnewswire.com/media/2711617/Innovative_Molecules_Logo.j-
pg

View original content: https://www.prnewswire.co.uk/news-
releases/innovative-molecules-completes-enrollment-of-phase-1b-
clinical-trial-of-im-250-302482334.html

Digital press kit: http://www.ots.at/pressemappe/PR180031/aom